The m6A regulator KIAA1429 stabilizes RAB27B mRNA and promotes the progression of chronic myeloid leukemia and resistance to targeted therapy

[1]  E. Jabbour,et al.  A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase , 2022, Journal of Hematology & Oncology.

[2]  A. Tiwari,et al.  m6A modification: recent advances, anticancer targeted drug discovery and beyond , 2022, Molecular cancer.

[3]  J. Doroshow,et al.  PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components , 2022, OncoTargets and therapy.

[4]  G. Martinelli,et al.  Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies , 2022, Journal of Hematology & Oncology.

[5]  L. Pang,et al.  Detailed resume of RNA m6A demethylases , 2022, Acta pharmaceutica Sinica. B.

[6]  O. Grzybowska-Izydorczyk,et al.  The outcomes of ponatinib therapy in patients with chronic myeloid leukemia resistant or intolerant to previous tyrosine kinase inhibitors, treated in Poland within the donation program , 2021, Clinical Lymphoma Myeloma and Leukemia.

[7]  S. Javed,et al.  A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic Drugs , 2021, Frontiers in Genetics.

[8]  K. Flynn,et al.  Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions , 2021, Current Hematologic Malignancy Reports.

[9]  W. Wang,et al.  Mettl3 inhibits the apoptosis and autophagy of chondrocytes in inflammation through mediating Bcl2 stability via Ythdf1-mediated m6A modification. , 2021, Bone.

[10]  Jianying Zhou,et al.  VIRMA contributes to non-small cell lung cancer progression via N6-methyladenosine-dependent DAPK3 post-transcriptional modification. , 2021, Cancer letters.

[11]  Zheng-lan Huang,et al.  Intracellular delivery of anti-BCR/ABL antibody by PLGA nanoparticles suppresses the oncogenesis of chronic myeloid leukemia cells , 2021, Journal of Hematology & Oncology.

[12]  B. Pang,et al.  YTHDF2 facilitates UBXN1 mRNA decay by recognizing METTL3-mediated m6A modification to activate NF-κB and promote the malignant progression of glioma , 2021, Journal of Hematology & Oncology.

[13]  C. Tisné,et al.  A comprehensive review of m6A/m6Am RNA methyltransferase structures , 2021, Nucleic acids research.

[14]  Andrew J. Bannister,et al.  Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia , 2021, Nature.

[15]  Ji-Fu Wei,et al.  Role of m6A methyltransferase component VIRMA in multiple human cancers (Review) , 2021, Cancer cell international.

[16]  Jun Zhou,et al.  Differential roles of YTHDF1 and YTHDF3 in embryonic stem cell-derived cardiomyocyte differentiation , 2020, RNA biology.

[17]  C. Schiffer,et al.  Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? , 2020, Haematologica.

[18]  Samie R. Jaffrey,et al.  A Unified Model for the Function of YTHDF Proteins in Regulating m6A-Modified mRNA , 2020, Cell.

[19]  Keqiu Jiang,et al.  Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux. , 2020, Carcinogenesis.

[20]  W. Xie,et al.  m6A-binding proteins: the emerging crucial performers in epigenetics , 2020, Journal of Hematology & Oncology.

[21]  B. Druker,et al.  Response and Resistance to BCR-ABL1-Targeted Therapies. , 2020, Cancer cell.

[22]  Jianjun Chen,et al.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. , 2020, Cancer cell.

[23]  Ming-Hai Wang,et al.  KIAA1429 regulates cell proliferation by targeting c‐Jun messenger RNA directly in gastric cancer , 2020, Journal of cellular physiology.

[24]  Katya Frazier,et al.  Emerging role of m6A RNA methylation in nutritional physiology and metabolism , 2020, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[25]  Jianjun Chen,et al.  The Biogenesis and Precise Control of RNA m6A Methylation. , 2019, Trends in genetics : TIG.

[26]  Shiqing Ma,et al.  Epigenetic Regulation of m6A Modifications in Human Cancer , 2019, Molecular therapy. Nucleic acids.

[27]  A. Tefferi,et al.  Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management , 2019, American journal of hematology.

[28]  Mengda Cao,et al.  KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner , 2019, Oncogene.

[29]  Liang Wang,et al.  KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m6A modification of ID2 mRNA , 2019, OncoTargets and therapy.

[30]  Chuan He,et al.  Where, When, and How: Context-Dependent Functions of RNA Methylation Writers, Readers, and Erasers. , 2019, Molecular cell.

[31]  A. Fatica,et al.  N6-Methyladenosine (m6A): A Promising New Molecular Target in Acute Myeloid Leukemia , 2019, Front. Oncol..

[32]  Hualiang Jiang,et al.  Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. , 2019, Cancer cell.

[33]  R. Flavell,et al.  RNA m6A modification and its function in diseases , 2018, Frontiers of Medicine.

[34]  Chuan He,et al.  VIRMA mediates preferential m6A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation , 2018, Cell Discovery.

[35]  G. Martinelli,et al.  Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy , 2018, Molecular Cancer.

[36]  Hao Zhou,et al.  miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding , 2018, Leukemia.

[37]  Yue Sheng,et al.  METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. , 2017, Cell stem cell.

[38]  John E. J. Rasko,et al.  Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia , 2017, Journal of Hematology & Oncology.

[39]  P. Ren,et al.  Overexpression of Rab27B is correlated with distant metastasis and poor prognosis in ovarian cancer. , 2016, Oncology letters.

[40]  J. Dengjel,et al.  Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells , 2016, Cell Communication and Signaling.

[41]  R. Xu,et al.  Leukemia stem cells: the root of chronic myeloid leukemia , 2015, Protein & Cell.

[42]  Schraga Schwartz,et al.  Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites. , 2014, Cell reports.

[43]  Jinhui Wang,et al.  ATRA-Induced Cellular Differentiation and CD38 Expression Inhibits Acquisition of BCR-ABL Mutations for CML Acquired Resistance , 2014, PLoS Genetics.

[44]  M. Fukuda.  Rab27 Effectors, Pleiotropic Regulators in Secretory Pathways , 2013, Traffic.

[45]  S. Hamm-Alvarez,et al.  Direct Imaging of RAB27B-Enriched Secretory Vesicle Biogenesis in Lacrimal Acinar Cells Reveals Origins on a Nascent Vesicle Budding Site , 2012, PloS one.

[46]  N. Udagawa,et al.  Rab27a and Rab27b are involved in stimulation‐dependent RANKL release from secretory lysosomes in osteoblastic cells , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[47]  M. Fukuda,et al.  The small GTPase Rab27B regulates amylase release from rat parotid acinar cells , 2004, Journal of Cell Science.

[48]  R. Burbano,et al.  Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model , 2021, In Vivo.

[49]  T. Lion,et al.  Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations. , 2021, American journal of cancer research.

[50]  Shaoguang Li,et al.  Leukemia Stem Cells in Chronic Myeloid Leukemia. , 2019, Advances in experimental medicine and biology.